[晚期非小细胞肺癌BRAF突变靶向治疗的研究进展]
[Research Progress of Targeted Therapy for BRAF Mutation in Advanced Non-small Cell Lung Cancer].
作者信息
Liu Xia, Zhong Diansheng
机构信息
Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China.
出版信息
Zhongguo Fei Ai Za Zhi. 2018 Aug 20;21(8):635-640. doi: 10.3779/j.issn.1009-3419.2018.08.10.
Abstract
Targeted therapy is one of the major treatment modalities in advanced non-small cell lung cancer (NSCLC) with sensitive driver gene mutations. BRAF is considered a promising oncogenic driver in NSCLC after the discovery of epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) fusion and ROS1 rearrangement. BRAF V600E mutation accounts for more than half of BRAF mutations, which is a potential therapeutic target for advanced NSCLC. This review aims to summarize the advancements of BRAF gene mutation and targeted therapy for BRAF mutation in NSCLC. .
摘要
靶向治疗是晚期非小细胞肺癌（NSCLC）伴有敏感驱动基因突变的主要治疗方式之一。在表皮生长因子受体（EGFR）突变、间变性淋巴瘤激酶（ALK）融合和ROS1重排被发现后，BRAF被认为是NSCLC中有前景的致癌驱动基因。BRAF V600E突变占BRAF突变的一半以上，是晚期NSCLC的潜在治疗靶点。本综述旨在总结BRAF基因突变及NSCLC中BRAF突变靶向治疗的进展。
相似文献
1
[Research Progress of Targeted Therapy for BRAF Mutation
in Advanced Non-small Cell Lung Cancer].[晚期非小细胞肺癌BRAF突变靶向治疗的研究进展]
Zhongguo Fei Ai Za Zhi. 2018 Aug 20;21(8):635-640. doi: 10.3779/j.issn.1009-3419.2018.08.10.
2
Targeting -Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.靶向 - 突变型非小细胞肺癌：从分子剖析到合理设计的治疗
Oncologist. 2017 Jul;22(7):786-796. doi: 10.1634/theoncologist.2016-0458. Epub 2017 May 9.
3
Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.携带BRAF突变的肺癌患者的临床特征与预后
Lung Cancer. 2016 Jan;91:23-8. doi: 10.1016/j.lungcan.2015.11.006. Epub 2015 Nov 15.
4
[Driver genes expression and clinical characteristics of targeted therapy in non-small cell lung cancer in Yunnan-Kweichow Plateau].[云贵高原非小细胞肺癌驱动基因表达及靶向治疗的临床特征]
Zhonghua Zhong Liu Za Zhi. 2020 Sep 23;42(9):735-740. doi: 10.3760/cma.j.cn112152-20200323-00248.
5
[Research Progress of Immune Checkpoint Inhibitor Therapy for BRAF Mutation
in Non-small Cell Lung Cancer].[BRAF 突变非小细胞肺癌免疫检查点抑制剂治疗的研究进展]
Zhongguo Fei Ai Za Zhi. 2019 Sep 20;22(9):583-589. doi: 10.3779/j.issn.1009-3419.2019.09.06.
6
[Progress in the Treatment of Non-small Cell Lung Cancer with BRAF Inhibitors].[BRAF抑制剂治疗非小细胞肺癌的研究进展]
Zhongguo Fei Ai Za Zhi. 2016 Oct 20;19(10):711-714. doi: 10.3779/j.issn.1009-3419.2016.10.13.
7
Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF non-small cell lung cancer.BRAF 非小细胞肺癌中 BRAF 和 MEK 抑制剂耐药的分子机制。
Eur J Cancer. 2020 Jun;132:211-223. doi: 10.1016/j.ejca.2020.03.025. Epub 2020 May 6.
8
Targeted therapy in lung cancer: Are we closing the gap in years of life lost?肺癌的靶向治疗：我们是否在弥补失去的生命年限？
Cancer Med. 2022 Sep;11(18):3417-3424. doi: 10.1002/cam4.4703. Epub 2022 Mar 22.
9
Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients.326 例连续西班牙非鳞状非小细胞肺癌患者中 EGFR、KRAS、BRAF 和 PIK3CA 突变与 ALK 重排的共存。
Clin Lung Cancer. 2017 Nov;18(6):e395-e402. doi: 10.1016/j.cllc.2017.04.006. Epub 2017 Apr 27.
10
[Research Progress of BRAF Fusion in Non-small Cell Lung Cancer].[BRAF融合在非小细胞肺癌中的研究进展]
Zhongguo Fei Ai Za Zhi. 2023 Oct 20;26(10):782-788. doi: 10.3779/j.issn.1009-3419.2023.101.28.
引用本文的文献
1
Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges.非小细胞肺癌中靶向治疗和免疫治疗的耐药机制：克服挑战的有前景策略
Front Immunol. 2024 Apr 9;15:1366260. doi: 10.3389/fimmu.2024.1366260. eCollection 2024.
2
[Research progress on the relationship between the Raf murine sarcoma viral oncogene homolog B gene mutation and lymph node metastasis of papillary thyroid carcinoma].[Raf鼠肉瘤病毒癌基因同源物B基因突变与甲状腺乳头状癌淋巴结转移关系的研究进展]
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2021 Feb 25;38(1):191-195. doi: 10.7507/1001-5515.202006040.
3
[Research Progress of Immune Checkpoint Inhibitor Therapy for BRAF Mutation
in Non-small Cell Lung Cancer].[BRAF 突变非小细胞肺癌免疫检查点抑制剂治疗的研究进展]
Zhongguo Fei Ai Za Zhi. 2019 Sep 20;22(9):583-589. doi: 10.3779/j.issn.1009-3419.2019.09.06.
本文引用的文献
1
An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to Dabrafenib Plus Trametinib.在对达拉非尼加曲美替尼耐药的BRAF V600E突变型肺腺癌中获得性NRAS Q61K突变
J Thorac Oncol. 2018 Aug;13(8):e131-e133. doi: 10.1016/j.jtho.2018.03.026. Epub 2018 Apr 6.
2
AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma.AXL/AKT 轴介导的 BRAF 抑制剂耐药性取决于黑色素瘤中的 PTEN 状态。
Oncogene. 2018 Jun;37(24):3275-3289. doi: 10.1038/s41388-018-0205-4. Epub 2018 Mar 19.
3
BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers.BRAF 和 MEK 抑制剂：在 BRAF 突变型癌症中的应用和耐药性。
Drugs. 2018 Apr;78(5):549-566. doi: 10.1007/s40265-018-0884-8.
4
FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring Mutations.FDA 批准概要：达拉非尼联合曲美替尼治疗携带突变的转移性非小细胞肺癌。
Oncologist. 2018 Jun;23(6):740-745. doi: 10.1634/theoncologist.2017-0642. Epub 2018 Feb 7.
5
Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.基于分子谱的晚期实体瘤的靶向治疗：MyPathway 研究的结果，一项开放标签、Ⅱa 期多篮子研究。
J Clin Oncol. 2018 Feb 20;36(6):536-542. doi: 10.1200/JCO.2017.75.3780. Epub 2018 Jan 10.
6
Dabrafenib plus trametinib in patients with previously untreated BRAF-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.达拉非尼联合曲美替尼治疗既往未经治疗的 BRAF 突变型转移性非小细胞肺癌的开放标签、2 期临床试验。
Lancet Oncol. 2017 Oct;18(10):1307-1316. doi: 10.1016/S1470-2045(17)30679-4. Epub 2017 Sep 11.
7
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.辅助达拉非尼联合曲美替尼治疗 BRAF 突变型 III 期黑色素瘤。
N Engl J Med. 2017 Nov 9;377(19):1813-1823. doi: 10.1056/NEJMoa1708539. Epub 2017 Sep 10.
8
An approach to suppress the evolution of resistance in BRAF-mutant cancer.一种抑制BRAF突变型癌症中耐药性演变的方法。
Nat Med. 2017 Aug;23(8):929-937. doi: 10.1038/nm.4369. Epub 2017 Jul 17.
9
Identification of the Serine Biosynthesis Pathway as a Critical Component of BRAF Inhibitor Resistance of Melanoma, Pancreatic, and Non-Small Cell Lung Cancer Cells.鉴定丝氨酸生物合成途径是黑色素瘤、胰腺和非小细胞肺癌细胞对 BRAF 抑制剂产生耐药性的关键组成部分。
Mol Cancer Ther. 2017 Aug;16(8):1596-1609. doi: 10.1158/1535-7163.MCT-16-0798. Epub 2017 May 12.
10
A meta-analysis of the association between BRAF mutation and nonsmall cell lung cancer.BRAF突变与非小细胞肺癌关联的荟萃分析。
Medicine (Baltimore). 2017 Apr;96(14):e6552. doi: 10.1097/MD.0000000000006552.
Zotero 插件